Neurodiagnostics specialist machineMD secures strategic investment from Topcon Healthcare

Bern-based medtech company machineMD has announced a strategic partnership with Topcon Healthcare. The collaboration aims to integrate machineMD’s neurodiagnostic technology with Topcon’s digital health platform, paving the way for earlier and more precise detection of neurological diseases within a connected care ecosystem.

Founded with the goal of transforming neurological disease diagnostics, machineMD is developing innovative tools based on oculometric analysis, using eye movements and pupil responses to assess brain function. Its flagship product, neos™, combines virtual reality (VR) with AI-driven analytics to objectively measure oculomotor and pupillary activity. Already in clinical use in Switzerland and the United States, neos™ is streamlining clinical workflows and enabling scalable, reimbursable neurodiagnostics.

Topcon Healthcare, a global leader in robotic diagnostics and ocular imaging, is leading the pre-Series A round, which targets a total raise of CHF 5 to 7 million. Existing investors will participate, and machineMD aims to secure an additional CHF 1 to 3 million from new partners to complete the round.

“Topcon Healthcare and machineMD share a bold ambition to shape the future of neurodiagnostics—making it more accessible, scalable, and data-driven,” said Dominic Senn, CEO and Co-Founder of machineMD.

Expanding access to neurodiagnostics through strategic integration and global growth

Through the partnership, machineMD’s functional neurodiagnostics will be integrated into Topcon’s Harmony platform, a cloud-based ecosystem that connects eyecare, primary care, and specialty providers. The synergy between ocular biomarkers and neurodiagnostic data will support faster and more effective decision-making across healthcare systems.

Ali Tafreshi, CEO and President of Topcon Healthcare, added: “Our investment in machineMD reflects our commitment to expanding ocular-based diagnostics into the realm of neurological diseases. machineMD’s expertise and cutting-edge technology will enable more precise and earlier diagnoses, ultimately improving patient outcomes.”

With the proceeds from the funding round, machineMD plans to accelerate commercialization, particularly in primary care and the US market, and conduct targeted studies on conditions like Parkinson’s, Alzheimer’s, and Multiple Sclerosis. The company’s long-term vision is to establish neurodiagnostics as a new standard of care, improving outcomes for millions affected by neurological disorders.